Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Return on Equity: 2020-2025

Historic Return on Equity for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -0.73%.

  • C4 Therapeutics' Return on Equity fell 29.00% to -0.73% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.73%, marking a year-over-year decrease of 29.00%. This contributed to the annual value of -0.46% for FY2024, which is 4.00% up from last year.
  • As of Q3 2025, C4 Therapeutics' Return on Equity stood at -0.73%, which was down 19.96% from -0.60% recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Return on Equity peaked at -0.21% during Q4 2021, and registered a low of -0.73% during Q3 2025.
  • For the 3-year period, C4 Therapeutics' Return on Equity averaged around -0.52%, with its median value being -0.50% (2025).
  • The largest annual percentage gain for C4 Therapeutics' Return on Equity in the last 5 years was 85bps (2021), contrasted with its biggest fall of 60bps (2021).
  • Quarterly analysis of 5 years shows C4 Therapeutics' Return on Equity stood at -0.21% in 2021, then dropped by 18bps to -0.39% in 2022, then declined by 19bps to -0.57% in 2023, then grew by 11bps to -0.46% in 2024, then decreased by 29bps to -0.73% in 2025.
  • Its Return on Equity stands at -0.73% for Q3 2025, versus -0.60% for Q2 2025 and -0.50% for Q1 2025.